The effect of daily administration of naproxen on the prothrombin complex activity in patients under long-term therapy with phenprocoumon.
Out of a total of 150 patients attending an out-patient clinic for anticoagulant therapy, 12 had disorders which normally would indicate a prolonged use of an antirheumatic drug. To 6 of these patients, naproxen (1/4 g twice daily) was given while anticoagulant treatment with phenprocoumon was continued in an unchanged dosage schedule (average dose 2.1 mg/day). On the average, the prothrombin complex activity (PP%) was reduced to a stable level 10--20% below that obtained during a 2-month period before the naproxen treatment was started. No bleeding episodes or other effects were observed. Thus the simultaneous administration of naproxen caused no problems for the maintenance of a stable anticoagulant therapy.
D015110:4-Hydroxycoumarins / Q000627:therapeutic use*; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects*; D001798:Blood Proteins; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D010644:Phenprocoumon / Q000627:therapeutic use*; D011485:Protein Binding / Q000187:drug effects; D011516:Prothrombin / Q000032:analysis*; D012216:Rheumatic Diseases / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
D015110:4-Hydroxycoumarins; D001798:Blood Proteins; D009288:Naproxen; D011516:Prothrombin; D010644:Phenprocoumon